THE CLINICAL FEATURES OF RADIOIODINE-RESISTANT DIFFERENTIATED THYROID CANCER: PRELIMINARY RESULTS
Introduction. According to global statistics, thyroid cancer is the seventh most common cancer among all types of cancer. Thyroid cancer treatment using radioactive iodine effectively eliminates the remnants of thyroid tissue that accumulate I131. It is worth noting that some patients may experience disease progression even with treatment. Radioiodine-resistant differentiated thyroid cancer is a complex malignancy with limited treatment options, making early diagnosis a key priority for physicians.
Aim: To investigate clinical features of radioiodine resistance in patients with highly differentiated thyroid cancer.
Materials and methods of the study. The study design is a retrospective study. A database of patients from all over Kazakhstan treated in the radionuclide therapy department of the Center for Nuclear Medicine and Oncology of the Abay region from January to December 2023 was formed. 445 medical records were analyzed. A representative sample of 229 patients was selected using Epi Info v5.5.15 software from those records. This sample has high reliability (97%) with an expected frequency of 50% and an error of 5%.
Results of the research and conclusion. In the study, 9.4% of 229 patients showed signs of refractoriness to radioiodine therapy. As a result, 4.5% of patients showed no radioiodine uptake in the areas of regional recurrence. Structural tumor progression was observed in 81%. Also, 9% of patients had tumors after radioiodine therapy without signs of remission. In addition, 4.5% of cases showed “Mismatch between I131 uptake on radioiodine SPECT/CT and 18F-FDG PET/CT”. It is essential to continue research in the direction of studying the resistance of patients to radioiodine therapy in order to clarify the influence of genetic factors on the response to I131 therapy. Further studies of these parameters remain relevant and require in-depth analysis.
Aidana M. Rakhmankulova1, https://orcid.org/0000-0003-3307-413X
Laura A. Pak1,2, https://orcid.org/0000-0002-5249-3359
Pavel O. Rumyantsev4, https://orcid.org/0000-0001-6998-7171
Lyudmila M. Pivina1, https://orcid.org/0000-0002-8035-4866
Nazigul S. Esbolatova3, https://orcid.org/0009-0005-3957-724X
Saltanat O. Bolsynbekova2, https://orcid.org/0009-0002-2462-1883
Dana M. Seitkhanova1, https://orcid.org/0009-0002-1331-7798
Azhar S. Baktiyar1, https://orcid.org/0009-0002-2075-4953
Arailym Baurzhan3, https://orcid.org/0000-0003-0279-6607
Dinara S. Zharlyganova2, https://orcid.org/0000-0001-6383-4035
Клинический протокол медицинского вмешательства. Радиойодтерапия. Протокол №148 Министерства здравоохранения Республики Казахстан от «23» сентября 2021 года.
2. Денисенко Н.П., Шуев Г.Н., Мухамадиев Р.Х., Перфильева О.М., Казаков Р.Е., Качанова А.А., Милютина О.И., Коненкова О.В., Рыжкин С.А., Иващенко Д.В., Буре И.В., Кириенко С.Л., Жмаева Е.М., Мирзаев К.Б., Аметов А.С., Поддубная И.В., Сычев Д.А. Генетические маркеры, ассоциированные с резистентностью к радиойодтерапии, у больных раком щитовидной железы. Современная Онкология. 2022/ 24(3):345–350. DOI: 10.26442/18151434.2022.3.201867
3. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun. 74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. PMID: 38572751.
4. Capdevila J., Galofré J.C., Grande E., Zafón Llopis C., Ramón Y Cajal Asensio T., Navarro González E., Jiménez-Fonseca P., Santamaría Sandi J., Gómez Sáez J.M., Riesco Eizaguirre G. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI). Clin Transl Oncol. 2017 Mar. 19(3):279-287. doi: 10.1007/s12094-016-1554-5. Epub 2016 Oct 4. PMID: 27704399.
5. Chan H.P., Chen I.F., Tsai F.R., Kao C.H., Shen D.H. Reversing "Flip-Flop" Phenomenon of 131 I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib. Clin Nucl Med. 2023 Mar 1. 48(3):e147-e148. doi: 10.1097/RLU.0000000000004475. Epub 2022 Nov 11. PMID: 36327463.
6. Diwanji D., Carrodeguas E., Seo Y., Kang H., Soe M.H., Chiang J.M., Zhang L., Liu C., Behr S.C., Flavell R.R. Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers. J Clin Med. 2024 Jul 6. 13(13):3963. doi: 10.3390/jcm13133963. PMID: 38999527, PMCID: PMC11242608.
7. Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., Caillou B., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006 Aug. 91(8):2892-9. doi: 10.1210/jc.2005-2838. Epub 2006 May 9. PMID: 16684830.
8. Giovanella L., Deandreis D., Vrachimis A., Campenni A., Petranovic Ovcaricek P. Molecular Imaging and Theragnostics of Thyroid Cancers. Cancers (Basel). 2022 Mar 1. 14(5):1272. doi: 10.3390/cancers14051272. PMID: 35267580. PMCID: PMC8909041.
9. Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., Pacini F., Randolph G.W., Sawka A.M., Schlumberger M., Schuff K.G., Sherman S.I., Sosa J.A., Steward D.L., Tuttle R.M., Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guiqdelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan. 26(1):1-133. doi: 10.1089/thy.2015.0020. PMID: 26462967; PMCID: PMC4739132.
10. Isoda T., BaBa S., Maruoka Y., Kitamura Y., Tahara K., Sasaki M., Honda H. Impact of patient age on the iodine/FDG "flip-flop" phenomenon in lung metastasis from thyroid cancer. Ann Nucl Med. 2016 Oct;30(8):518-24. doi: 10.1007/s12149-016-1104-9. Epub 2016 Jul 5. PMID: 27380042.
11. Li G., Lei J., Song L., Jiang K., Wei T., Li Z., Gong R., Zhu J. Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas. Cancer Med. 2018 Nov;7(11):5448-5456. doi: 10.1002/cam4.1794. Epub 2018 Sep 27. PMID: 30264548; PMCID: PMC6246937.
12. Liu Y., Wang J., Hu X., Pan Z., Xu T., Xu J., Jiang L., Huang P., Zhang Y., Ge M. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resist Updat. 2023 May. 68:100939. doi: 10.1016/j.drup.2023.100939. Epub 2023 Feb 8. PMID: 36806005.
13. Liu Y., Liu C., Pan Y. et al. Pyruvate carboxylase promotes malignant transformation of papillary thyroid carcinoma and reduces iodine uptake. Cell Death Discov. 8, 423 (2022). https://doi.org/10.1038/s41420-022-01214-y
14. Vaisman F., Carvalho D.P., Vaisman M. A new appraisal of iodine refractory thyroid cancer. Endocr Relat Cancer. 2015 Dec. 22(6):R301-10. doi: 10.1530/ERC-15-0300. Epub 2015 Aug 25. PMID: 26307020.
15. Yavuz S., Puckett Y. Iodine-131 Uptake Study. In: Stat Pearls. Stat Pearls Publishing, Treasure Island (FL); 2023. PMID: 32644709.
Количество просмотров: 104
Категория статей:
Оригинальное исследование
Библиографическая ссылка
Rakhmankulova A.M., Pak L.A., Rumyantsev P.O., Pivina L.M., Esbolatova N.S., Bolsynbekova S.O., Seitkhanova D.M., Baktiyar A.S., Baurzhan A., Zharlyganova D.S. Тhe clinical features of radioiodine-resistant differentiated thyroid cancer: preliminary results // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (5), pp. 25-32. doi 10.34689/SH.2024.26.5.003Похожие публикации:
USING THE ROBSON CLASSIFICATION TO ESTIMATE THE CAESAREAN SECTION RATE AND LOOK FOR WAYS TO REDUCE IT
CURRENT PRACTICE IN CARING FOR PEOPLE WITH DEMENTIA
АНAЛИЗ РЕЗУЛЬТАТОВ YЛЬТРAЗВYКOВOЙ ДИAГНOCТИКИ C ДOППЛEРOГРAФИEЙ ПРИ ДOБРOКAЧECТВEННЫX И ЗЛOКAЧECТВEННЫX OПYXOЛЯX ЩИТOВИДНOЙ ЖЕЛEЗЫ
EFFECT OF SEASONAL CHANGES ON SCORPION POISON
THERAPEUTIC EFFECTS OF MELATONIN IN AN ETHANOL-INDUCED GASTRIC ULCER MODEL